

CHAO HUANG

Partner

Fangda Partners

+86 10 5769 5652

+86 138 1175 2043

chao.huang@fangdalaw.com



PRACTICE AREAS

MR. HUANG SPECIALIZES IN M&A, PRIVATE EQUITY INVESTMENTS AND ONSHORE OFFERING AND LISTING OF SECURITIES.

REPRESENTATIVE MATTERS AND CASES

M&A and private equity investments:

- Advised WuXi AppTec (603259.SH/2359.HK) on its acquisition of 100% equity stake in HD Biosciences Co., Ltd., its acquisition of 100% equity stake in Jiangsu Safe Pharmaceutical Co., Ltd., and the establishment of a joint venture offering healthcare big data solutions
- Advised CICC Capital on its acquisition of the majority stake in Shell Zhejiang
- Advised China National Integrated Circuit Industry Investment Fund on its investments in a number of PRC listed or unlisted semiconductor enterprises, including SMIT (2239.HK), Navtech (300456.SZ), AMEC (688012.SH) and Centec
- Advised VeriSilicon (688521.SH) and AMEC (688012.SH) on their onshore and offshore restructuring and multiple rounds of equity financing
- Advised Avary Holding (002938.SZ) and WuXi AppTec (603259.SH/2359.HK) on their pre-IPO equity financing, and COFCO W&W on its equity financing
- Advised multiple private equity firms including Fonestone Capital and CEC Innovation Fund on various types of investments primarily focusing on the non-financial institutions' payment services, internet content provider and semiconductor industries

Onshore offering and listing of securities:

- Advised VeriSilicon (688521.SH) on its IPO and A-share listing on the STAR Market of the Shanghai Stock Exchange
- Advised AMEC (688012.SH) on its IPO and A-share listing on the STAR Market of the Shanghai Stock Exchange
- Advised WuXi AppTec (603259.SH/2345.HK) on its IPO and A-share listing on the Main Board of the Shanghai Stock Exchange
- Advised Konruns Pharmaceutical (603590.SH) on its IPO and A-share listing on the Main Board of the Shanghai Stock Exchange
- Advised Sichuan Haowu Electromechanical Co., Ltd. (000787.SZ) on its issuance of shares and cash payments in its acquisition of Neijiang Pengxiang Investment Co., Ltd.
- Advised the sole sponsor and underwriter on Maxscend's (300782.SZ) IPO and A-share listing on the Growth Enterprises Market of the Shenzhen Stock Exchange
- Advised the co-lead underwriter on CATL's (300750.SZ) IPO and A-share listing on the Growth Enterprises Market of the Shenzhen Stock Exchange
- Advised the sponsor or the underwriter on the non-public A-share offerings of multiple companies, including Yiling Pharmaceutical (002603.SZ) and Yibai Pharmaceutical (600594.SH)
- Advised the underwriter on China Molybdenum Co., Ltd.'s (603993.SH/3993.HK) public offering of A-share convertible bonds in the amount of RMB 4.9 billion
- Advised Synbio Technology (871854) on its listing on the National Equities Exchange and Quotations

OTHER INFORMATION

Education

- New York University School of Law, LL.M., Hauser Global Scholar, 2020
- Peking University Law School, LL.M., 2013
- Peking University National School of Development, Bachelor of Economics, 2011
- Peking University Law School, LL.B., 2011

Professional Qualification

- Admitted to practice in the PRC

Professional Background

Mr. Huang joined Fangda in 2015. Before joining the firm, he worked at another first-tier PRC law firm in Beijing.